CN109476730A - 治疗阿尔茨海默病的方法 - Google Patents

治疗阿尔茨海默病的方法 Download PDF

Info

Publication number
CN109476730A
CN109476730A CN201780044190.9A CN201780044190A CN109476730A CN 109476730 A CN109476730 A CN 109476730A CN 201780044190 A CN201780044190 A CN 201780044190A CN 109476730 A CN109476730 A CN 109476730A
Authority
CN
China
Prior art keywords
subject
antibody
amount
administering
body weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780044190.9A
Other languages
English (en)
Chinese (zh)
Inventor
B.P.布特
J.J.塞维尼
L.L.威廉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen International Neuroscience GmbH
Original Assignee
Biogen International Neuroscience GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen International Neuroscience GmbH filed Critical Biogen International Neuroscience GmbH
Priority to CN202210397569.0A priority Critical patent/CN114796481A/zh
Priority to CN202210397435.9A priority patent/CN114931635A/zh
Publication of CN109476730A publication Critical patent/CN109476730A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201780044190.9A 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法 Pending CN109476730A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202210397569.0A CN114796481A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法
CN202210397435.9A CN114931635A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662346818P 2016-06-07 2016-06-07
US62/346,818 2016-06-07
US201662435531P 2016-12-16 2016-12-16
US62/435,531 2016-12-16
PCT/EP2017/063711 WO2017211827A1 (en) 2016-06-07 2017-06-06 Methods for treating alzheimer's disease

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202210397569.0A Division CN114796481A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法
CN202210397435.9A Division CN114931635A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法

Publications (1)

Publication Number Publication Date
CN109476730A true CN109476730A (zh) 2019-03-15

Family

ID=59067640

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201780044190.9A Pending CN109476730A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法
CN202210397569.0A Pending CN114796481A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法
CN202210397435.9A Pending CN114931635A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202210397569.0A Pending CN114796481A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法
CN202210397435.9A Pending CN114931635A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法

Country Status (12)

Country Link
US (2) US20200308259A1 (enExample)
EP (1) EP3464350A1 (enExample)
JP (3) JP2019517540A (enExample)
KR (2) KR20230165883A (enExample)
CN (3) CN109476730A (enExample)
AU (2) AU2017276656A1 (enExample)
BR (1) BR112018075300A2 (enExample)
CA (1) CA3026598A1 (enExample)
IL (1) IL263433B2 (enExample)
MA (1) MA45149A (enExample)
MX (1) MX2018015022A (enExample)
WO (1) WO2017211827A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110511276A (zh) * 2019-08-13 2019-11-29 王跃驹 植物作为宿主在表达Aducanumab抗体中的应用
CN114343605A (zh) * 2020-11-19 2022-04-15 和人人工知能科技有限公司 利用大脑影像的阿尔茨海默病的生物学分类装置及方法
CN114599393A (zh) * 2019-10-22 2022-06-07 比奥根Ma公司 治疗阿尔茨海默病的抗β-淀粉样蛋白抗体

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
EP3696192A1 (en) 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease
WO2020193644A1 (en) 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF
JP2023535024A (ja) 2020-07-23 2023-08-15 オター プロシーナ リミテッド 抗ａベータ抗体
US20240270830A1 (en) * 2021-06-07 2024-08-15 Biogen Ma Inc. Methods for treating alzheimer's disease
US20250122146A1 (en) * 2021-09-30 2025-04-17 The Scripps Research Institute Compounds for reducing neuroinflammation
IL312715A (en) * 2021-11-19 2024-07-01 Ap Biosciences Inc Bispecific antibodies targeting cd137 and uses thereof for anti-cancer immunotherapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101516911A (zh) * 2006-07-14 2009-08-26 Ac免疫有限公司 针对淀粉状蛋白β的人源化抗体
CN101622275A (zh) * 2007-01-05 2010-01-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
WO2014089500A1 (en) * 2012-12-07 2014-06-12 Biogen Idec International Neuroscience Gmbh A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES
CN105164156A (zh) * 2012-10-15 2015-12-16 米迪缪尼有限公司 针对β淀粉样蛋白的抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2627672T (lt) 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
JP6284548B2 (ja) 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト抗タウ抗体
NZ723884A (en) * 2014-02-08 2023-02-24 Genentech Inc Methods of treating alzheimer’s disease
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101516911A (zh) * 2006-07-14 2009-08-26 Ac免疫有限公司 针对淀粉状蛋白β的人源化抗体
CN101622275A (zh) * 2007-01-05 2010-01-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
CN105164156A (zh) * 2012-10-15 2015-12-16 米迪缪尼有限公司 针对β淀粉样蛋白的抗体
WO2014089500A1 (en) * 2012-12-07 2014-06-12 Biogen Idec International Neuroscience Gmbh A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JACOPO C. DIFRANCESCO等: "Anti-Aβ autoantibodies in amyloid related imaging abnormalities (ARIA):candidate biomarker for immunotherapy in Alzheimer’s disease and cerebral amyloid angiopathy", 《FRONTIERS IN NEUROLOGY》 *
JEFF SEVIGNY等: "ADUCANUMAB (BIIB037), AN ANTI-AMYLOID BETA MONOCLONAL ANTIBODY, IN PATIENTS WITH PRODROMAL OR MILD ALZHEIMER’S DISEASE: INTERIM RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, PHASE 1B STUDY", 《ALZHEIMER"S AND DEMENTIA:THE JOURNAL OF THE ALZHEIMER"S ASSOCIATION》 *
WAGNER ZAGO等: "Vascular alterations in PDAPP mice after anti-Ab immunotherapy:Implications for amyloid-related imaging abnormalities", 《ALZHEIMER’S & DEMENTIA 》 *
张建华等: "抗β-淀粉样多肤抗体治疗阿尔茨海默病研究进展", 《中华病理学杂质》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110511276A (zh) * 2019-08-13 2019-11-29 王跃驹 植物作为宿主在表达Aducanumab抗体中的应用
CN114599393A (zh) * 2019-10-22 2022-06-07 比奥根Ma公司 治疗阿尔茨海默病的抗β-淀粉样蛋白抗体
CN114343605A (zh) * 2020-11-19 2022-04-15 和人人工知能科技有限公司 利用大脑影像的阿尔茨海默病的生物学分类装置及方法

Also Published As

Publication number Publication date
MA45149A (fr) 2019-04-10
EP3464350A1 (en) 2019-04-10
US20200308259A1 (en) 2020-10-01
IL263433A (en) 2019-01-31
WO2017211827A1 (en) 2017-12-14
MX2018015022A (es) 2019-08-14
KR20190021311A (ko) 2019-03-05
CN114931635A (zh) 2022-08-23
AU2017276656A1 (en) 2018-12-13
IL263433B1 (en) 2023-11-01
IL263433B2 (en) 2024-03-01
CA3026598A1 (en) 2017-12-14
AU2024216442A1 (en) 2024-10-17
BR112018075300A2 (pt) 2019-04-30
CN114796481A (zh) 2022-07-29
JP2022145965A (ja) 2022-10-04
KR20230165883A (ko) 2023-12-05
JP2019517540A (ja) 2019-06-24
JP2025160337A (ja) 2025-10-22
US20220281963A1 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
CN109476730A (zh) 治疗阿尔茨海默病的方法
JP2023011002A (ja) アルツハイマー病の治療法
KR20220084095A (ko) 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체
US8722042B2 (en) Use of ventricular enlargement rate in intravenous immunoglobulin treatment of alzheimer's disease
JP2024532438A (ja) 抗Ａβプロトフィブリル抗体の皮下製剤及びその使用方法
KR20250078929A (ko) 알츠하이머병 치료를 위한 면역치료법과 사일로이노시톨 병용
JP2025506389A (ja) ｐ－タウ１８１レベルを使用した治療方法
JP2025182058A (ja) アルツハイマー病の治療法
TW202313111A (zh) 治療阿茲海默症之方法
NZ788486A (en) Methods for treating Alzheimer's disease
AU2012227191A1 (en) Use Of Ventricular Enlargement Rate In Intravenous Immunoglobulin Treatment Of Alzheimer's Disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190315